Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound salvia miltiorrhiza, commonly known as Compound Danshen Dripping Pills (CDDP) or Fufang Danshen Diwan, is a standardized Traditional Chinese Medicine (TCM) formulation. It primarily consists of extracts from *Salvia miltiorrhiza* (Danshen), *Panax notoginseng* (Sanqi), and synthetic or natural Borneol. Developed primarily by Tasly Pharmaceuticals, it is widely used for the treatment and prevention of cardiovascular diseases, including chronic stable angina and coronary heart disease. The drug's mechanism of action involves improving coronary microcirculation, inhibiting platelet aggregation, reducing blood viscosity, and providing anti-inflammatory and antioxidant effects. It is formulated as dropping pills (dripping pills) designed for oral or sublingual administration to facilitate rapid absorption. In the United States, a standardized version known as T89 or Dantonic has undergone Phase 3 clinical trials for the treatment of chronic stable angina, making it one of the first TCM products to reach late-stage clinical development under the FDA's botanical drug pathway.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound salvia miltiorrhiza.